Hanmi Pharmaceutical, Beijing Hanmi progress cancer therapy BH3120 with promising trial results
Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical are making significant strides in the development of BH3120, a next-generation cancer immunotherapy. Updates on the innovative treatment were ... Read More
Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies
Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial ... Read More